Magenta Therapeutics Return on Equity

Magenta Therapeutics (MGTA) currently reports a ROE of -16.4%. That is below the Healthcare sector average of 22.01%. Use the charts on this page to explore Magenta Therapeutics's ROE history and peer comparisons.

Magenta Therapeutics's ROE of -16.4% is lower than the Healthcare sector average of 22.01%. That is roughly 174.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Magenta Therapeutics's current -16.4% should be judged against Healthcare norms (sector average: 22.01%) and against MGTA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -16.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Magenta Therapeutics, and consider following MGTA for alerts when major investors trade the stock.

Magenta Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -16.4% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MGTA with unrelated industries.